Compositions and methods for treating non-alcoholic steatohepatitis
Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH).
1. A method for treating or alleviating non-alcoholic steatohepatitis (NASH), comprising administering eicosapentaenoic acid, ethyl eicosapentanoate, or a combination thereof at a dosage of 0.6 g or 0.9 g three times per day to a human subject, wherein the administering results in one or more of:
an increase of at least 1% to about 95% of serum adiponectin concentration,
an increase of 1% to about 90% of albumin concentration,
a reduction of at least 1% to about 50% of glycated hemoglobin (HbA1c) concentration,
a reduction of 1% to about 90% of alkaline phosphatase (ALP) concentration,
a reduction of at least 1% to about 95% of Type IV collagen 7S concentration, or
a reduction of at least 1% to about 95% of hyaluronic acid concentration; and
wherein the administering results in:
at least 1% increase of interleukin-10 (IL-10) concentration,
at least 1% lower of small dense LDL concentration, or
a concentration reduction of at least 1% to about 95% of: interleukin-2 (IL-2); interleukin-3 receptor alpha chain; apolipoproteinA-IV; apolipoproteinC-II; chemokine (C-C motif) ligand 2 (CCL2); thrombospondin 1 (TSP1); lymphocyte antigen 6 complex locus D; matrix metallopeptidase 12 (MMP12); matrix metallopeptidase 13 (MMP13); trehalase; tissue inhibitor of metalloproteinase 1 (TIMP1); procollagen type I alpha 1 (COL1a1); tumor necrosis factor receptor (TNFR) superfamily member 19; tumor necrosis factor alpha induced protein (TNFAIP) 6; very low density lipoprotein receptor (VLDLR); lipoprotein lipase; eosinophil associated ribonuclease (EAR) A1, EAR-A2, EAR-A3, EAR-A12; or any combination thereof;
in the subject.
2. The method of claim 1 , wherein the subject is not diabetic.
3. The method of claim 1 , wherein the subject is not taking any anti-diabetic drug.
4. The method of claim 1 , comprising administering the ethyl eicosapentanoate to the subject.
5. The method of claim 1 , wherein the administering is continued for 3, 6, 9, or 12 months.
6. The method of claim 1 , wherein the eicosapentaenoic acid, ethyl eicosapentanoate, or a combination thereof is dosed at 0.6 g three times per day.
7. The method of claim 1 , wherein the eicosapentaenoic acid, ethyl eicosapentanoate, or a combination thereof is dosed at 0.9 g three times per day.
8. The method of claim 1 , wherein the eicosapentaenoic acid, ethyl eicosapentanoate, or a combination thereof is in a form of a self-emulsifying composition.
9. The method of claim 1 , wherein the administering results in at least 1% increase of interleukin-10 (IL-10) concentration in the subject.
10. The method of claim 1 , wherein the administering results in at least 1% lower of small dense LDL concentration in the subject.
11. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of interleukin-2 (IL-2) in the subject.
12. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of interleukin-3 receptor alpha chain in the subject.
13. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of apolipoproteinA-IV, apolipoproteinC-II, or a combination thereof, in the subject.
14. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of chemokine (C-C motif) ligand 2 (CCL2) in the subject.
15. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of thrombospondin 1 (TSP1) in the subject.
16. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of lymphocyte antigen 6 complex locus D in the subject.
17. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 13 (MMP13), or a combination thereof, in the subject.
18. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of trehalase in the subject.
19. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of tissue inhibitor of metalloproteinase 1 (TIMP1) in the subject.
20. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of procollagen type I alpha 1 (COL1a1) in the subject.
21. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of tumor necrosis factor receptor (TNFR) superfamily member 19 in the subject.
22. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of tumor necrosis factor alpha induced protein (TNFAIP) 6 in the subject.
23. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of very low density lipoprotein receptor (VLDLR) in the subject.
24. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of lipoprotein lipase in the subject.
25. The method of claim 1 , wherein the administering results in a concentration reduction of at least 1% to about 95% of eosinophil associated ribonuclease (EAR) A1, EAR-A2, EAR-A3, EAR-A12, or any combination thereof, in the subject.
26. The method of claim 1 , wherein the subject is a possible or definite NASH subject.